Joseph Cherian

10 Biopolis Road, Chromos #05-01
Singapore, 138670, Singapore

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Correction to "Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity".

Correction to "Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity".

Journal: Journal of medicinal chemistry
Published: December 23, 2025

In Silico-Enabled Discovery and Development of Potent and Selective CDK11 Inhibitors.

In Silico-Enabled Discovery and Development of Potent and Selective CDK11 Inhibitors.

Journal: ChemMedChem
Published: October 08, 2025

Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity.

Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity.

Journal: Journal of medicinal chemistry
Published: August 07, 2025

Identification of small-molecule binding sites of a ubiquitin-conjugating enzyme-UBE2T through fragment-based screening.

Identification of small-molecule binding sites of a ubiquitin-conjugating enzyme-UBE2T through fragment-based screening.

Journal: Protein science : a publication of the Protein Society
Published: November 13, 2023

Identification and characterization of inhibitors covalently modifying catalytic cysteine of UBE2T and blocking ubiquitin transfer.

Identification and characterization of inhibitors covalently modifying catalytic cysteine of UBE2T and blocking ubiquitin transfer.

Journal: Biochemical and biophysical research communications
Published: November 04, 2023

Ultra-large scale virtual screening identifies a small molecule inhibitor of the Wnt transporter Wntless.

Ultra-large scale virtual screening identifies a small molecule inhibitor of the Wnt transporter Wntless.

Journal: iScience
Published: September 03, 2023

Fragment-based Discovery of a Small-Molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues.

Fragment-based Discovery of a Small-Molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues.

Journal: ACS medicinal chemistry letters
Published: November 12, 2018

Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.

Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.

Journal: European journal of medicinal chemistry
Published: May 07, 2018

Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors.

Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors.

Journal: Journal of medicinal chemistry
Published: April 25, 2018

Escherichia coli Topoisomerase IV E Subunit and an Inhibitor Binding Mode Revealed by NMR Spectroscopy.

Escherichia coli Topoisomerase IV E Subunit and an Inhibitor Binding Mode Revealed by NMR Spectroscopy.

Journal: The Journal of biological chemistry
Published: May 10, 2016

Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.

Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.

Journal: Journal of medicinal chemistry
Published: March 25, 2016

Characterization of the interaction between Escherichia coli topoisomerase IV E subunit and an ATP competitive inhibitor.

Characterization of the interaction between Escherichia coli topoisomerase IV E subunit and an ATP competitive inhibitor.

Journal: Biochemical and biophysical research communications
Published: October 06, 2015
Showing 1-12 of 17

Last Updated: 09/26/2026